company background image
SRPT logo

Sarepta Therapeutics NasdaqGS:SRPT Stock Report

Last Price

US$129.46

Market Cap

US$12.2b

7D

3.6%

1Y

-4.8%

Updated

28 Mar, 2024

Data

Company Financials +

Sarepta Therapeutics, Inc.

NasdaqGS:SRPT Stock Report

Market Cap: US$12.2b

SRPT Stock Overview

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.

SRPT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Sarepta Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sarepta Therapeutics
Historical stock prices
Current Share PriceUS$129.46
52 Week HighUS$159.89
52 Week LowUS$55.25
Beta0.93
1 Month Change-8.53%
3 Month Change34.25%
1 Year Change-4.83%
3 Year Change69.87%
5 Year Change6.97%
Change since IPO231.95%

Recent News & Updates

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 02
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Recent updates

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 02
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth

Feb 06
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth

Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval

Jan 22

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jan 10
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate

There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues

Dec 20
There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues

Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?

Nov 29
Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Aug 08
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Apr 30
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Jan 17
Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001

Sep 29

Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027

Sep 12

Sarepta says FDA lifted clinical hold on Duchenne candidate

Sep 06

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Aug 22
Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses

Aug 08

Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder

Jul 29

Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?

May 09
Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?

Sarepta: The DMD Leader

Apr 26

Sarepta: Still A Solid Long-Term Bet On Sales And Next Generation Treatments

Feb 09

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

Feb 07
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

A Look At The Intrinsic Value Of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Dec 06
A Look At The Intrinsic Value Of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sarepta: Revenue Keeps Rising While We Wait For Functional Data

Nov 01

Health Check: How Prudently Does Sarepta Therapeutics (NASDAQ:SRPT) Use Debt?

Nov 01
Health Check: How Prudently Does Sarepta Therapeutics (NASDAQ:SRPT) Use Debt?

Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?

Jul 19
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?

Sarepta Therapeutics: Faultlines May Run Deeper Than Assumed

Jun 02

Most Shareholders Will Probably Agree With Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Compensation

May 27
Most Shareholders Will Probably Agree With Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Compensation

Sarepta Therapeutics EPS beats by $0.03, beats on revenue

May 05

Shareholder Returns

SRPTUS BiotechsUS Market
7D3.6%0.9%0.2%
1Y-4.8%11.0%28.1%

Return vs Industry: SRPT underperformed the US Biotechs industry which returned 11% over the past year.

Return vs Market: SRPT underperformed the US Market which returned 28.1% over the past year.

Price Volatility

Is SRPT's price volatile compared to industry and market?
SRPT volatility
SRPT Average Weekly Movement6.9%
Biotechs Industry Average Movement11.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: SRPT's share price has been volatile over the past 3 months.

Volatility Over Time: SRPT's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19801,314Doug Ingramhttps://www.sarepta.com

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.

Sarepta Therapeutics, Inc. Fundamentals Summary

How do Sarepta Therapeutics's earnings and revenue compare to its market cap?
SRPT fundamental statistics
Market capUS$12.22b
Earnings (TTM)-US$535.98m
Revenue (TTM)US$1.24b

9.8x

P/S Ratio

-22.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SRPT income statement (TTM)
RevenueUS$1.24b
Cost of RevenueUS$1.03b
Gross ProfitUS$215.61m
Other ExpensesUS$751.58m
Earnings-US$535.98m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-5.71
Gross Margin17.34%
Net Profit Margin-43.11%
Debt/Equity Ratio144.1%

How did SRPT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.